RAPT Therapeutics, Inc.
RAPTNASDAQHealthcare
$58.01
+$0.00(+0.00%)
Market Cap$959257107
P/E Ratio—
52W High$58.02
52W Low$5.6652
RAPT Therapeutics, Inc. (RAPT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RAPT · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 5, 2026EPS Actual
-$9.12
Est. -$0.82 · -1008.2%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 5, 2026
After Market Close
▼ Miss EPS
RAPT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 5, 2026 | -$0.82 | -$9.12 | -1008.2% | — | — | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.88 | -$0.65 | +26.1% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.61 | -$0.65 | -6.6% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$2.48 | -$0.64 | +74.2% | — | — | — |
| ▼ Q1 FY2025 | Mar 6, 2025 | -$0.45 | -$1.14 | -153.3% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.56 | -$0.47 | +16.1% | — | — | — |
| ▲ Q3 FY2024 | Aug 8, 2024 | -$0.74 | -$0.71 | +4.0% | — | — | — |
| ▼ Q2 FY2024 | May 9, 2024 | -$0.78 | -$0.79 | -1.3% | — | — | — |
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
-$9.12
EPS Est.
-$0.82
EPS Surpr.
-1008.2%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.65
EPS Est.
-$0.88
EPS Surpr.
+26.1%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.65
EPS Est.
-$0.61
EPS Surpr.
-6.6%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.64
EPS Est.
-$2.48
EPS Surpr.
+74.2%
Revenue
—
Q1 FY2025
Mar 6, 2025Miss
EPS Actual
-$1.14
EPS Est.
-$0.45
EPS Surpr.
-153.3%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.47
EPS Est.
-$0.56
EPS Surpr.
+16.1%
Revenue
—
Q3 FY2024
Aug 8, 2024Beat
EPS Actual
-$0.71
EPS Est.
-$0.74
EPS Surpr.
+4.0%
Revenue
—
Q2 FY2024
May 9, 2024Miss
EPS Actual
-$0.79
EPS Est.
-$0.78
EPS Surpr.
-1.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.97 | $-0.97 | $-0.97 | 1 |
| Q3 FY2027 | $-0.94 | $-0.94 | $-0.94 | 1 |
| Q2 FY2027 | $-0.90 | $-0.90 | $-0.90 | 1 |
| Q1 FY2027 | $-0.88 | $-0.88 | $-0.88 | 1 |
| Q4 FY2026 | $-0.88 | $-0.88 | $-0.88 | 1 |
| Q3 FY2026 | $-0.81 | $-0.81 | $-0.81 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 5, 2026 | -1008.2% | $58.01 | $58.01 | +0.00% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +26.1% | $28.27 | $29.04 | +2.72% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -6.6% | $9.99 | $10.25 | +2.60% |
| ▲ Q2 FY2025 | May 8, 2025 | +74.2% | $6.40 | $6.40 | +0.00% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -153.3% | $9.04 | $8.96 | -0.88% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +16.1% | $14.00 | $13.92 | -0.57% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +4.0% | $19.28 | $18.88 | -2.07% |
| ▼ Q2 FY2024 | May 9, 2024 | -1.3% | $63.84 | $37.28 | -41.60% |
Q1 FY2026+0.00%
Report Date
Mar 5, 2026
EPS Beat/Miss
-1008.2%
Price Before
$58.01
Price After
$58.01
Q4 FY2025+2.72%
Report Date
Nov 6, 2025
EPS Beat/Miss
+26.1%
Price Before
$28.27
Price After
$29.04
Q3 FY2025+2.60%
Report Date
Aug 7, 2025
EPS Beat/Miss
-6.6%
Price Before
$9.99
Price After
$10.25
Q2 FY2025+0.00%
Report Date
May 8, 2025
EPS Beat/Miss
+74.2%
Price Before
$6.40
Price After
$6.40
Q1 FY2025-0.88%
Report Date
Mar 6, 2025
EPS Beat/Miss
-153.3%
Price Before
$9.04
Price After
$8.96
Q4 FY2024-0.57%
Report Date
Nov 12, 2024
EPS Beat/Miss
+16.1%
Price Before
$14.00
Price After
$13.92
Q3 FY2024-2.07%
Report Date
Aug 8, 2024
EPS Beat/Miss
+4.0%
Price Before
$19.28
Price After
$18.88
Q2 FY2024-41.60%
Report Date
May 9, 2024
EPS Beat/Miss
-1.3%
Price Before
$63.84
Price After
$37.28
Avg Beat Reaction+0.02%
Avg Miss Reaction-9.97%
Beat Rate4 / 8 quarters
Largest Move-41.60% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RAPT ends December
RAPT Therapeutics, Inc. (RAPT) most recently reported earnings on March 5, 2026 for Q1 FY2026, posting EPS of $-9.12 — missing the analyst consensus of $-0.82 by -1008.2%. The next RAPT earnings date is expected around September 1, 2026.
Each quarter, investors track RAPT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RAPT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RAPT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RAPT earnings · 5 questionsRAPT Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. RAPT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RAPT historically reports after market close (AMC).
RAPT earnings datewhen is RAPT earningsRAPT next earnings datewhen does RAPT report earningsRAPT earnings calendar
▸ Source: FMP · RAPT Therapeutics, Inc. SEC filings · US GAAP · RAPT Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026